Comparative Pharmacology
Head-to-head clinical analysis: MYIDYL versus TOLAK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYIDYL versus TOLAK.
MYIDYL vs TOLAK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
c-Met/ALK inhibitor; inhibits receptor tyrosine kinases MET and ALK, blocking downstream signaling pathways including PI3K/AKT and RAS/RAF/MEK/ERK, leading to reduced tumor cell proliferation and angiogenesis.
TOLAK (tazarotene) is a retinoid prodrug that is converted to its active metabolite tazarotenic acid, which binds selectively to retinoic acid receptors (RARs) such as RARβ and RARγ; this modulates gene expression involved in cell proliferation, differentiation, and inflammation.
50 mg orally twice daily without regard to meals.
Adults: 200 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours (range 10–14 hours) in adults with normal renal function; prolonged in renal impairment (up to 24–30 hours).
The terminal elimination half-life of fluorouracil is approximately 10-20 minutes due to rapid catabolism by dihydropyrimidine dehydrogenase. Clinically, this short half-life necessitates continuous infusion for sustained systemic exposure.
Primarily renal excretion as unchanged drug (~60%) and metabolites (~30%); biliary/fecal excretion accounts for ~10%.
Tolak (fluorouracil) is primarily eliminated via metabolism; less than 10% is excreted unchanged in urine. Fecal excretion accounts for approximately 10-20% of the administered dose.
Category C
Category C
Antifungal
Antifungal